Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Capital Expenditures (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Capital Expenditures for 12 consecutive years, with $126000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 500.0% to $126000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $188000.0, a 408.11% increase, with the full-year FY2025 number at $188000.0, up 408.11% from a year prior.
  • Capital Expenditures was $126000.0 for Q4 2025 at Ekso Bionics Holdings, up from $12000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $141000.0 in Q3 2022 to a low of -$1000.0 in Q4 2021.
  • A 5-year average of $41071.4 and a median of $30500.0 in 2024 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 5400.0% in 2022, then plummeted 87.94% in 2023.
  • Ekso Bionics Holdings' Capital Expenditures stood at -$1000.0 in 2021, then surged by 5400.0% to $53000.0 in 2022, then dropped by 18.87% to $43000.0 in 2023, then plummeted by 51.16% to $21000.0 in 2024, then soared by 500.0% to $126000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Capital Expenditures are $126000.0 (Q4 2025), $12000.0 (Q3 2025), and $40000.0 (Q2 2025).